Enveric Biosciences, Inc. SEC filings ENVB
Enveric Biosciences, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jul 30, 2001. Its latest annual report, Form ARS, was filed on Apr 14, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 14, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | May 4, 2026 | — |
| EFFECT | Filing | Apr 29, 2026 | — |
| CORRESP | Letter to the SEC | Apr 28, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 27, 2026 | — |
| EFFECT | Filing | Feb 17, 2026 | — |
| CORRESP | Letter to the SEC | Feb 17, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 17, 2026 | — |
| D | Filing | Feb 11, 2026 | — |
| EFFECT | Filing | Dec 30, 2025 | — |
| CORRESP | Letter to the SEC | Dec 29, 2025 | — |
| D | Filing | Dec 23, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 23, 2025 | — |
| EFFECT | Filing | Dec 8, 2025 | — |
| CORRESP | Letter to the SEC | Dec 8, 2025 | — |
| D | Filing | Oct 3, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2025 | — |
| EFFECT | Filing | Apr 17, 2025 | — |
| CORRESP | Letter to the SEC | Apr 16, 2025 | — |
| EFFECT | Filing | Jan 30, 2025 | — |
| CORRESP | Letter to the SEC | Jan 30, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 21, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 19, 2024 | — |
| PRER14A | Filing | Dec 12, 2024 | — |
| EFFECT | Filing | Sep 11, 2024 | — |
| CORRESP | Letter to the SEC | Sep 10, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 9, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2024 | — |
| EFFECT | Filing | Jan 22, 2024 | — |
| CORRESP | Letter to the SEC | Jan 19, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 16, 2024 | — |
| EFFECT | Filing | Dec 5, 2023 | — |
| CORRESP | Letter to the SEC | Dec 4, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 5, 2023 | — |
| CORRESP | Letter to the SEC | Jun 8, 2023 | — |
| UPLOAD | Letter from the SEC | May 15, 2023 | — |
| D/A | Filing | Apr 19, 2023 | — |
| EFFECT | Filing | Aug 11, 2022 | — |
| CORRESP | Letter to the SEC | Aug 9, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 9, 2022 | — |
| D | Filing | Aug 5, 2022 | — |
| 8-A12G/A | Filing | May 17, 2022 | — |
| 8-A12G | Filing | May 4, 2022 | — |
| 425 | Filing | Sep 3, 2021 | — |
| 425 | Filing | Aug 18, 2021 | — |
| EFFECT | Filing | Aug 6, 2021 | — |
| CORRESP | Letter to the SEC | Aug 4, 2021 | — |
| EFFECT | Filing | Jul 9, 2021 | — |
| CORRESP | Letter to the SEC | Jul 8, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2021 | — |
| 425 | Filing | Jul 6, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 25, 2021 | — |
| 425 | Filing | Jun 8, 2021 | — |
| EFFECT | Filing | Apr 7, 2021 | — |
| CORRESP | Letter to the SEC | Apr 5, 2021 | — |
| NT 10-K | Filing | Apr 1, 2021 | Dec 31, 2020 |
| D | Filing | Feb 24, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 19, 2021 | — |
| D | Filing | Jan 20, 2021 | — |
| 25-NSE | Delisting notice | Dec 30, 2020 | — |
| 425 | Filing | Dec 23, 2020 | — |
| 425 | Filing | Dec 18, 2020 | — |
| EFFECT | Filing | Nov 12, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 10, 2020 | — |
| CORRESP | Letter to the SEC | Nov 10, 2020 | — |
| CORRESP | Letter to the SEC | Nov 10, 2020 | — |
| CORRESP | Letter to the SEC | Nov 9, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 5, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 2, 2020 | — |
| CORRESP | Letter to the SEC | Oct 22, 2020 | — |
| CORRESP | Letter to the SEC | Oct 20, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 7, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2020 | — |
| CORRESP | Letter to the SEC | Sep 16, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 27, 2020 | — |
| CORRESP | Letter to the SEC | Aug 12, 2020 | — |
| CORRESP | Letter to the SEC | Aug 12, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 30, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2020 | — |
| 425 | Filing | Jun 2, 2020 | — |
| 425 | Filing | Feb 27, 2020 | — |
| 425 | Filing | Jan 27, 2020 | — |
| 425 | Filing | Jan 21, 2020 | — |
| 425 | Filing | Jan 16, 2020 | — |
| EFFECT | Filing | Nov 19, 2019 | — |
| CORRESP | Letter to the SEC | Nov 15, 2019 | — |
| CORRESP | Letter to the SEC | Nov 12, 2019 | — |
| CORRESP | Letter to the SEC | Nov 8, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 22, 2019 | — |
| EFFECT | Filing | Nov 21, 2018 | — |
| CORRESP | Letter to the SEC | Nov 20, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2018 | — |
| EFFECT | Filing | Oct 23, 2018 | — |
| CORRESP | Letter to the SEC | Oct 22, 2018 | — |
| CORRESP | Letter to the SEC | Oct 22, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 19, 2018 | — |
| CORRESP | Letter to the SEC | Oct 18, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 18, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 18, 2018 | — |
| D/A | Filing | Aug 28, 2018 | — |
| D | Filing | Aug 2, 2018 | — |
| EFFECT | Filing | Nov 17, 2017 | — |
| CORRESP | Letter to the SEC | Nov 17, 2017 | — |
| EFFECT | Filing | Nov 9, 2017 | — |
| CERTNAS | Auto-generated paper document | Nov 9, 2017 | — |
| 8-A12B | Filing | Nov 9, 2017 | — |
| CORRESP | Letter to the SEC | Nov 8, 2017 | — |
| CORRESP | Letter to the SEC | Nov 8, 2017 | — |
| CORRESP | Letter to the SEC | Nov 7, 2017 | — |
| CORRESP | Letter to the SEC | Nov 7, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 29, 2017 | — |
| EFFECT | Filing | Jun 30, 2017 | — |
| CORRESP | Letter to the SEC | Jun 29, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 13, 2017 | — |
| UPLOAD | Letter from the SEC | May 3, 2017 | — |
| 425 | March 13, 2017 | Mar 13, 2017 | — |
| UPLOAD | Letter from the SEC | Mar 6, 2017 | — |
| NT 10-Q | Filing | Nov 17, 2015 | Sep 30, 2015 |
| SC 14F1 | Filing | May 27, 2015 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2010 | — |
| UPLOAD | Letter from the SEC | Feb 23, 2010 | — |
| UPLOAD | Letter from the SEC | Feb 2, 2010 | — |
| CORRESP | Letter to the SEC | Jan 22, 2010 | — |
| UPLOAD | Letter from the SEC | Dec 31, 2009 | — |
| NT 10-Q | Spatializer audio laboratories, inc. form 12b-25 | Nov 16, 2009 | Sep 30, 2009 |
| UPLOAD | Letter from the SEC | Aug 10, 2009 | — |
| CORRESP | Letter to the SEC | Aug 6, 2009 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2009 | — |
| UPLOAD | Letter from the SEC | May 27, 2009 | — |
| CORRESP | Letter to the SEC | Apr 22, 2009 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2009 | — |
| CORRESP | Letter to the SEC | Apr 8, 2009 | — |
| NT 10-K | Form 12b-25 | Mar 31, 2009 | Mar 31, 2009 |
| UPLOAD | Letter from the SEC | Mar 30, 2009 | — |
| CORRESP | Letter to the SEC | Mar 19, 2009 | — |
| UPLOAD | Letter from the SEC | Feb 18, 2009 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2009 | — |
| CORRESP | Letter to the SEC | Feb 2, 2009 | — |
| SC 14F1 | Schedule 14f-1 | May 7, 2008 | — |
| REGDEX | Auto-generated paper document | Jun 5, 2007 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2006 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2005 | — |
| CORRESP | Letter to the SEC | Aug 8, 2005 | — |
| 10-K405 | 10-k405 for year ending 12-31-2001 | Mar 28, 2002 | Dec 31, 2001 |
| AW | Filing | Nov 28, 2001 | — |
| AW | Withdrawal request | Nov 28, 2001 | — |
Showing 146 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ENVB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 890821
- Former names
- AMERI Holdings, Inc. (until Dec 30, 2020); SPATIALIZER AUDIO LABORATORIES INC (until May 27, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.